AIM5 Antibody

What is AIM/CD5L and what are its primary functions?

AIM/CD5L is a protein expressed on various immune cells, including T cells, B cells, and natural killer cells. It belongs to the scavenger receptor cysteine-rich (SRCR) superfamily and was initially identified as an inducible cell surface ligand of CD5. The protein has several critical biological functions:

• Regulation of immune responses through modulation of T cell activation and cytokine production

• Anti-inflammatory effects in various physiological and pathological contexts

• Supporting macrophage survival and enhancing their viability

• Functioning in the thymus as an inducer of resistance to apoptosis within CD4+/CD8+ thymocytes

• Supporting the viability of thymocytes before thymic selection

This protein is also known by several aliases including AIM, Spalpha, apoptosis inhibitor 6, CD5 antigen-like, and IgM-associated peptide .

How do I optimize immunohistochemistry protocols for AIM/CD5L antibody?

For optimal immunohistochemistry results with AIM/CD5L antibody:

• Tissue preparation: Fix tissues in 10% neutral buffered formalin for 24-48 hours followed by paraffin embedding.

• Antigen retrieval: Use heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0) for 20 minutes.

• Primary antibody incubation: Dilute AIM/CD5L antibody (such as PA5-20242 or A01795) to 1:200-1:500 and incubate overnight at 4°C .

• Detection system: Use a polymer-based detection system with HRP/DAB for visualization.

• Controls: Include both positive controls (such as Raji cell lysate) and negative controls .

• Optimization: Titrate antibody concentration and adjust incubation time based on your specific tissue type and fixation methods.

The antibody can be stored at 4°C for three months or at -20°C for up to one year. Avoid repeated freeze-thaw cycles and prolonged exposure to high temperatures to maintain antibody integrity .

What are the common applications for AIM/CD5L antibody in immunological research?

AIM/CD5L antibody has several important applications in immunological research:

• Western blotting: For detection and quantification of AIM/CD5L protein expression in cell or tissue lysates. The observed molecular weight is approximately 68 kDa, though the calculated molecular weight is approximately 38 kDa .

• Immunohistochemistry: To visualize the distribution and localization of AIM/CD5L in tissue sections, particularly useful in studies examining immune cell infiltration and activation .

• ELISA: For quantitative measurement of AIM/CD5L levels in serum, plasma, or cell culture supernatants .

• Functional studies: To investigate the role of AIM/CD5L in:

  • T cell activation and cytokine production

  • Macrophage survival and function

  • Inflammatory response regulation

  • Autoimmune disease mechanisms

  • Cancer immunology

• Therapeutic development: As a tool in developing and evaluating potential therapeutic approaches targeting AIM/CD5L for autoimmune disorders, cancer, and infectious diseases .

How does AIM/CD5L antibody specificity affect the interpretation of contradictory experimental results?

When faced with contradictory experimental results using AIM/CD5L antibodies, consider the following factors:

• Antibody specificity: Different antibodies may recognize distinct epitopes on AIM/CD5L protein. The epitope location (e.g., near the carboxy terminus in the case of A01795) may affect accessibility depending on protein conformation or interaction with binding partners .

• Cross-reactivity: Some antibodies may cross-react with other proteins containing similar structural motifs. For example, AIM/CD5L belongs to the SRCR superfamily, which has multiple members with structural similarities .

• Isoform recognition: Multiple isoforms of AIM/CD5L exist, and different antibodies may recognize specific isoforms or shared epitopes. Verify which isoforms your antibody recognizes .

• Validation methods: Different validation methods (Western blot, IHC, ELISA) may yield different results due to how the protein is presented (denatured vs. native, etc.).

• Experimental context: Cell type, activation state, and microenvironment can all affect AIM/CD5L expression and epitope accessibility.

To resolve contradictory results:

• Use multiple antibodies targeting different epitopes

• Employ genetic approaches (siRNA, CRISPR) to confirm specificity

• Include appropriate positive and negative controls

• Consider the effects of sample preparation on epitope availability

• Validate findings using complementary techniques

What are the current advances in AI-based antibody design for AIM/CD5L targeting?

Recent advances in AI-based antibody design have revolutionized approaches to targeting proteins like AIM/CD5L:

• Integrated AI protocols: Advanced protocols like IsAb2.0 integrate state-of-the-art AI-based and physical methods for antibody design. These approaches can be applied to design antibodies targeting AIM/CD5L with improved specificity and affinity .

• Template-free modeling: AI tools like AlphaFold-Multimer (2.3/3.0) enable accurate modeling and complex construction without templates, which is particularly valuable for designing novel antibodies against targets like AIM/CD5L .

• Optimization algorithms: Precise methods such as FlexddG provide in silico antibody optimization to enhance binding affinity and other properties .

• Workflow improvements: Modern antibody design protocols have streamlined workflows that:

  • Require only antibody and antigen sequences as input

  • Generate 3D structures of antibody-antigen complexes

  • Identify hotspots through alanine scanning

  • Predict beneficial point mutations

• Humanization and affinity maturation: AI approaches facilitate both humanization of antibodies (reducing immunogenicity) and subsequent affinity maturation to restore or enhance binding capacity .

The application of these technologies to AIM/CD5L targeting could accelerate therapeutic antibody development for treating autoimmune disorders, cancer, and infectious diseases where this protein plays a regulatory role.

How do post-translational modifications of AIM/CD5L affect antibody recognition and function?

Post-translational modifications (PTMs) of AIM/CD5L can significantly impact antibody recognition and function:

• Glycosylation effects:

  • AIM/CD5L contains multiple potential N-glycosylation sites

  • Glycosylation patterns can mask epitopes or create steric hindrance

  • Different cell types or activation states may produce differently glycosylated forms

  • Antibodies raised against bacterially-expressed recombinant protein (lacking glycosylation) may not recognize native glycosylated protein effectively

• Phosphorylation impacts:

  • Phosphorylation can alter protein conformation

  • May affect antibody binding if the epitope includes or is near a phosphorylation site

  • Can influence protein-protein interactions that might mask epitopes

• Proteolytic processing:

  • AIM/CD5L may undergo proteolytic cleavage in certain contexts

  • Antibodies targeting regions affected by cleavage may show differential recognition

  • May produce unexpected banding patterns in Western blots

• Experimental considerations:

  • Sample preparation methods can affect PTMs (e.g., phosphatase activity during extraction)

  • Tissue/cell source influences PTM patterns

  • Disease states may alter PTM profiles

To address these challenges, researchers should:

• Use multiple antibodies targeting different epitopes

• Consider using antibodies specifically designed to recognize or be insensitive to particular PTMs

• Include appropriate controls reflecting the expected PTM status

• Employ complementary techniques to confirm findings

• Consider using enzymatic treatments (e.g., glycosidases, phosphatases) to assess PTM contributions

What are the optimal conditions for using AIM/CD5L antibody in Western blotting?

For optimal Western blotting results with AIM/CD5L antibody:

• Sample preparation:

  • Extract proteins using RIPA or NP-40 buffer containing protease inhibitors

  • Quantify protein concentration and load 20-50 μg per lane

  • Denature samples in reducing buffer at 95°C for 5 minutes

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal resolution

  • Include molecular weight markers spanning 25-100 kDa range

  • Run at 100-120V until dye front reaches bottom of gel

• Transfer conditions:

  • Transfer to PVDF membrane (preferred over nitrocellulose)

  • Use semi-dry or wet transfer at 100V for 60-90 minutes

  • Verify transfer using reversible stain

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute primary AIM/CD5L antibody at 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3x with TBST, 5-10 minutes each

• Detection:

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000)

  • Develop using enhanced chemiluminescence (ECL) substrate

  • Expected band size is approximately 68 kDa

• Controls and troubleshooting:

  • Include positive control (Raji cell lysate recommended)

  • Verify specificity with blocking peptide where available (e.g., PEP-0361 for PA5-20242)

  • If multiple bands appear, optimize antibody concentration and washing steps

How can AIM/CD5L antibody be effectively used in T cell functional assays?

AIM/CD5L antibody can be instrumental in T cell functional assays, providing insights into immune regulation mechanisms:

• T cell activation assays:

  • Pre-incubate purified T cells with AIM/CD5L antibody (5-10 μg/ml) for 1 hour

  • Stimulate cells with anti-CD3/CD28 or specific antigens

  • Measure activation markers (CD69, CD25) by flow cytometry

  • Assess proliferation using CFSE dilution or 3H-thymidine incorporation

  • Compare with isotype control antibody treatment

• Cytokine production assessment:

  • Treat T cells with AIM/CD5L antibody during activation

  • Collect supernatants at 24, 48, and 72 hours

  • Measure cytokine levels (IL-2, IFN-γ, IL-4, IL-17) by ELISA or cytometric bead array

  • Alternatively, perform intracellular cytokine staining and flow cytometry

• Antigen-specific T cell responses:

  • Culture antigen-presenting cells in AIM-V culture medium (serum-free, protein-free defined medium designed for T cell expansion)

  • Pulse with specific peptides (e.g., at 30 μg/ml)

  • Irradiate cells (e.g., 30 Gy X-ray)

  • Co-culture with T cells at defined ratios (e.g., E:T of 40:1 or 20:1)

  • Measure IFN-γ production using ELISPOT assays

• Signaling pathway analysis:

  • Stimulate T cells in presence or absence of AIM/CD5L antibody

  • Lyse cells at various timepoints (5, 15, 30 minutes)

  • Perform Western blotting for phosphorylated signaling molecules

  • Assess impact on TCR-proximal and downstream signaling events

• Co-culture systems:

  • Establish co-cultures of T cells with other immune cells (e.g., macrophages)

  • Add AIM/CD5L antibody to block or detect AIM/CD5L-mediated interactions

  • Evaluate outcomes on both cell types to understand bidirectional communication

What considerations are important when developing an ELISA for AIM/CD5L detection?

Developing a robust ELISA for AIM/CD5L detection requires careful consideration of several key factors:

• Antibody pair selection:

  • Use antibodies recognizing non-overlapping epitopes

  • Verify compatibility through preliminary testing

  • Consider one monoclonal (for capture) and one polyclonal (for detection)

  • Ensure antibodies maintain recognition in native conditions

• Assay format optimization:

  • Test both direct and sandwich ELISA formats

  • For sandwich ELISA: optimize capture antibody concentration (typically 1-10 μg/ml)

  • Determine optimal detection antibody dilution (typically 0.5-2 μg/ml)

  • Evaluate blocking buffers (BSA vs. casein vs. non-fat milk)

• Standard curve preparation:

  • Use recombinant AIM/CD5L protein of high purity

  • Prepare standards in the same matrix as samples

  • Create a wide dynamic range (e.g., 0-1000 ng/ml)

  • Include standards on each plate to account for plate-to-plate variation

• Sample considerations:

  • Determine appropriate sample dilutions through pilot testing

  • Consider matrix effects in different sample types (serum, plasma, cell culture)

  • Evaluate need for sample pre-treatment (e.g., heat inactivation)

  • Include spike-recovery experiments to assess accuracy

• Protocol optimization:

  • Test different incubation times and temperatures

  • Optimize washing steps (number, volume, buffer composition)

  • Evaluate substrate options for ideal sensitivity and signal-to-noise ratio

  • Establish appropriate stopping criteria

• Validation parameters:

  • Determine assay sensitivity (lower limit of detection and quantification)

  • Assess specificity using related proteins

  • Evaluate precision (intra- and inter-assay CV%)

  • Confirm linearity, accuracy, and reportable range

• Quality control:

  • Include positive and negative controls on each plate

  • Prepare quality control samples at low, medium, and high concentrations

  • Monitor assay drift and implement appropriate quality metrics

  • Consider including a blocking peptide control where available

How is AIM/CD5L antibody being used in autoimmune disease research?

AIM/CD5L antibody is increasingly utilized in autoimmune disease research due to the protein's immunoregulatory functions:

• Mechanistic studies:

  • Investigating AIM/CD5L's role in modulating T cell activation and cytokine production in autoimmune contexts

  • Examining interactions between AIM/CD5L and other immune regulators in disease development

  • Assessing how AIM/CD5L affects autoantigen presentation and recognition

• Biomarker development:

  • Evaluating AIM/CD5L levels in patient samples as potential diagnostic or prognostic markers

  • Correlating AIM/CD5L expression with disease activity, progression, or treatment response

  • Developing standardized ELISA protocols for clinical application

• Therapeutic targeting:

  • Designing antibodies that modulate AIM/CD5L function for therapeutic purposes

  • Utilizing AI-based antibody design approaches to develop humanized antibodies with optimal properties

  • Testing antibody-based interventions in preclinical models of autoimmune diseases

• Tissue-specific investigations:

  • Characterizing AIM/CD5L expression in affected tissues using immunohistochemistry

  • Correlating expression patterns with immune cell infiltration and tissue damage

  • Identifying cell populations expressing AIM/CD5L in different disease contexts

• Genetic associations:

  • Exploring how genetic variants affecting AIM/CD5L expression or function influence disease susceptibility

  • Investigating epigenetic regulation of AIM/CD5L in autoimmune conditions

  • Correlating genotype with protein expression and function

Current research suggests that AIM/CD5L's anti-inflammatory properties make it a promising target for therapeutic development in autoimmune conditions, with antibodies serving as both research tools and potential therapeutic agents .

What are the challenges in developing therapeutic antibodies targeting AIM/CD5L?

Developing therapeutic antibodies targeting AIM/CD5L presents several significant challenges:

• Target complexity:

  • AIM/CD5L has multiple functional domains and isoforms

  • The protein participates in diverse biological processes

  • Cell type-specific effects complicate therapeutic targeting

  • Different epitopes may trigger distinct functional outcomes

• Antibody design challenges:

  • Achieving high specificity while minimizing off-target effects

  • Balancing affinity with appropriate tissue penetration

  • Designing antibodies that modulate function in desired direction (inhibition vs. activation)

  • Overcoming limitations in current computational prediction methods

• Translation to therapeutic applications:

  • Humanization may reduce antibody affinity, requiring affinity maturation

  • Immunogenicity concerns for long-term administration

  • Predicting human responses from preclinical models

  • Potential toxicities from altering immune regulation pathways

• Technical limitations:

  • Current antibody design protocols like IsAb2.0 still face accuracy issues in predicting beneficial mutations

  • Computational methods may require manual intervention, limiting automation

  • Expensive computing requirements for some AI-based approaches

  • Limited validation data for novel computational prediction methods

• Therapeutic delivery considerations:

  • Determining optimal routes of administration

  • Achieving therapeutic concentrations at target sites

  • Addressing pharmacokinetic and pharmacodynamic variability

  • Developing appropriate biomarkers to monitor target engagement

Researchers are addressing these challenges through advanced methods including AI-based antibody design (e.g., IsAb2.0), which integrates AlphaFold-Multimer for structure prediction and FlexddG for affinity optimization . While promising, these approaches still require experimental validation and refinement to improve prediction accuracy and streamline workflows.

How can researchers validate and troubleshoot AIM/CD5L antibody-based experiments?

Effective validation and troubleshooting of AIM/CD5L antibody experiments require systematic approaches:

• Antibody validation strategies:

  • Verify specificity using multiple antibodies targeting different epitopes

  • Confirm target recognition through knockdown/knockout experiments

  • Test reactivity in both human and mouse samples if using cross-reactive antibodies

  • Use blocking peptides where available (e.g., PEP-0361 for PA5-20242)

  • Include appropriate positive controls (e.g., Raji cell lysate)

• Western blot troubleshooting:

  • For weak signals: increase antibody concentration, extend incubation time, or use more sensitive detection methods

  • For multiple bands: optimize antibody dilution, increase washing stringency, or verify with another antibody

  • For background issues: adjust blocking conditions, reduce antibody concentration, or increase washing steps

  • Always check for the expected molecular weight (~68 kDa)

• Immunohistochemistry optimization:

  • Test multiple antigen retrieval methods

  • Titrate primary antibody concentration

  • Evaluate different detection systems

  • Include appropriate positive and negative tissue controls

  • Counterstain to provide contextual information

• ELISA troubleshooting:

  • For poor standard curves: check reagent quality and preparation

  • For low signals: increase sample concentration or antibody amount

  • For high background: optimize blocking and washing steps

  • For poor reproducibility: standardize all incubation times and temperatures

• Experimental design considerations:

  • Include biological and technical replicates

  • Blind analysis where possible

  • Use appropriate statistical methods

  • Document all experimental conditions thoroughly

  • Consider antibody lot-to-lot variations

What future research directions will advance our understanding of AIM/CD5L biology?

Future research directions that will advance our understanding of AIM/CD5L biology include:

• Advanced structural studies:

  • Utilizing AI-based modeling approaches like AlphaFold-Multimer to predict AIM/CD5L interactions with binding partners

  • Conducting crystallography or cryo-EM studies of AIM/CD5L in complex with its receptors

  • Mapping functional domains through structure-function analyses

• Systems biology approaches:

  • Integrating proteomics, transcriptomics, and metabolomics to understand AIM/CD5L's broader impact

  • Developing computational models of AIM/CD5L's role in immune network regulation

  • Identifying feedback loops and regulatory mechanisms involving AIM/CD5L

• Single-cell technologies:

  • Using single-cell RNA-seq to identify cell populations expressing AIM/CD5L

  • Characterizing heterogeneity in AIM/CD5L expression and response

  • Implementing spatial transcriptomics to map AIM/CD5L expression in tissue contexts

• Therapeutic development:

  • Applying IsAb2.0 and other AI-based antibody design protocols to develop therapeutic antibodies

  • Creating humanized antibodies with optimized binding and functional properties

  • Designing targeted delivery systems for AIM/CD5L-modulating therapies

• Translational research:

  • Establishing AIM/CD5L as a biomarker in various diseases

  • Correlating genetic variants with AIM/CD5L function and disease susceptibility

  • Conducting intervention studies targeting AIM/CD5L in preclinical models

• Methodological innovations:

  • Developing improved antibodies with enhanced specificity and sensitivity

  • Creating reporter systems to monitor AIM/CD5L expression and activity

  • Establishing standardized protocols for AIM/CD5L detection and functional assessment